BriaCell Therapeutics Corp. (BCTX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BCTX Insider Trading Activity
BCTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Insider Activity of BriaCell Therapeutics Corp.
Over the last 12 months, insiders at BriaCell Therapeutics Corp. have bought $0 and sold $0 worth of BriaCell Therapeutics Corp. stock.
On average, over the past 5 years, insiders at BriaCell Therapeutics Corp. have bought $1.12M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 902,935 shares for transaction amount of $2M was made by Lustig Marc () on 2024‑05‑14.
List of Insider Buy and Sell Transactions, BriaCell Therapeutics Corp.
| 2024-05-14 | Lustig Marc | 902,935 5.6265% | $2.21 | $2M | -69.84% | |||
| 2022-12-28 | Bondarenko Jamieson | Chairman | 28,000 0.3608% | $4.58 | $128,240 | +40.80% | ||
| 2022-12-20 | Bondarenko Jamieson | director | 22,000 0.3311% | $5.35 | $117,700 | +21.44% |
Insider Historical Profitability
| Lustig Marc | 2542935 44.4926% | $7.48M | 1 | 0 | ||
| Bondarenko Jamieson | Chairman | 169856 2.9719% | $499,376.64 | 2 | 0 | +31.12% |
Historical Insider Profitability vs. Competitors
$85,897,100 | 36 | 2.47% | $15.94M | |
$1,363,112 | 33 | 15.03% | $20.3M | |
$94,084,626 | 29 | -21.08% | $18.77M | |
$226,127 | 22 | -27.62% | $14.26M | |
$11,247,055 | 15 | -26.49% | $20.16M | |
$122,973 | 15 | -26.96% | $14.96M | |
$1,199,157 | 14 | 7.52% | $15.3M | |
$39,336,371 | 14 | -17.87% | $14.56M | |
$70,584,874 | 10 | 3.97% | $16.62M | |
$36,538,405 | 10 | -21.99% | $19M | |
$20,715,938 | 10 | -42.51% | $20.33M | |
$189,648 | 9 | -52.20% | $17.19M | |
$456,220 | 9 | 34.12% | $19.12M | |
$2,891,537 | 8 | -39.31% | $13.97M | |
$26,000,000 | 5 | -56.00% | $16.73M | |
$2,060,158 | 5 | -21.35% | $14.45M | |
$82,917 | 4 | -11.54% | $19.68M | |
BriaCell Therapeutics Corp. (BCTX) | $245,940 | 2 | 31.12% | $16.8M |
$29,875 | 1 | -22.05% | $16.9M |
BCTX Institutional Investors: Active Positions
| Increased Positions | 14 | +53.85% | 20,240 | +72.54% |
| Decreased Positions | 11 | -42.31% | 16,818 | -60.27% |
| New Positions | 7 | New | 12,170 | New |
| Sold Out Positions | 6 | Sold Out | 14,308 | Sold Out |
| Total Postitions | 29 | +11.54% | 31,325 | +12.26% |
BCTX Ownership Change vs Market
Institutional Investor Ownership
| Group One Trading Llc | $18.00 | 0.08% | 4,526 | +2,000 | +79.18% | 2024-12-31 |
| Cantor Fitzgerald, L. P. | $15.00 | 0.06% | 3,734 | +3,734 | New | 2024-12-31 |
| Susquehanna International Group, Llp | $13.00 | 0.06% | 3,374 | +2,447 | +263.97% | 2024-12-31 |
| Virtu Financial Llc | $13.00 | 0.05% | 3,244 | +3,244 | New | 2024-12-31 |
| Ubs Group Ag | $11.00 | 0.04% | 2,641 | +2,588 | +4,883.02% | 2024-12-31 |
| Lpl Financial Llc | $10.00 | 0.04% | 2,617 | +600 | +29.75% | 2024-12-31 |
| Hrt Financial Lp | $10.00 | 0.04% | 2,533 | -2,420 | -48.86% | 2024-12-31 |
| Bank Of Montreal /Can/ | $9.00 | 0.04% | 2,336 | -19 | -0.81% | 2024-12-31 |
| Jane Street Group, Llc | $8.00 | 0.03% | 1,977 | +1,977 | New | 2024-12-31 |
| Hightower Advisors, Llc | $7.00 | 0.03% | 1,642 | +667 | +68.41% | 2024-12-31 |